Nanoethics and Regulations

As the science and technology of nanomedicine speed ahead, ethics, policy, and the law struggle to catch up also chases after it. It is important to proactively address the ethical, social and regulatory aspects of nanomedicine to minimize its adverse impacts on the environment and public health and to avoid a public backlash. In the next 10–15 years, nanotechnology is likely to revolutionize the practice of medicine and have a significant impact on human health. Nanotechnology is already contributing to the development of new drugs, biologics, and medical devices and the augmentation of existing therapeutics. Over 200 companies are involved in nanomedicine research and development. The U.S. Food and Drug Administration has approved nine different types of therapies that employ nanoscale materials, including products used for medical testing and imaging, drug delivery, wound healing, and bone and tissue repair. Discoveries and innovations in nanomedicine have occurred at a breath taking pace in just a short time, uses of nanotechnology in medicine have moved from laboratory testing, to clinical trials, to medical applications.

 

  • Innovative Practice
  • Clinical Research
  • Ethical Advancement of Medicine

Related Conference of Nanoethics and Regulations

July 27-28, 2026

39th World Congress on Pharmacology

Rome, Italy
July 27-28, 2026

19th World Drug Delivery Summit

Paris, France
September 14-15, 2026

6th International Conference on Pharmaceutical Chemistry

Paris, France
September 24-25, 2026

6th World Congress on Rare Diseases & Orphan Drugs

Paris, France
November 26-27, 2026

5th World Conference on Pharma Industry and Medical Devices

Zurich, Switzerland
November 26-27, 2026

5th World Congress on Precision and Personalized Medicine

Zurich, Switzerland